ClinicalTrials.gg
CompletedNCT03061331Updated Oct 2, 2018Results posted

Lumacaftor/Ivacaftor Combination Therapy in Subjects With CF Who Have an A455E CFTR Mutation

A Phase 2 interventional study of LUM/IVA and Placebo in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 2 sites in Netherlands. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2018-10-02.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing lumacaftor in Cystic Fibrosis — none open to participants now, none under way, none of them phase 3. lumacaftor · Cystic Fibrosis.

Enrollment
20th of 20
20 · median 66
Started
2017
with 1 other
Phase 2
4 of 20
none open now
Registered
16th of 20
by date
Lead sponsor
20 of 20
Vertex Pharmaceuticals Incorporated

Among the 20 studies testing lumacaftor in Cystic Fibrosis, this one is the 20th largest by enrollment, is one of 2 that started in 2017, is one of 4 in phase 2, and was the 16th registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

None of the 20 studies testing lumacaftor in Cystic Fibrosis is open now. The open studies under Cystic Fibrosis, anywhere →

About lumacaftor

lumacaftor: first FDA approval 2015 (ORKAMBI), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies testing lumacaftor in Cystic Fibrosis as a file.
02

Study summary

This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter, crossover study that will evaluate the efficacy of LUM/IVA in subjects with CF 12 years of age and older who have at least one A455E mutation.

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female with confirmed diagnosis of CF
  • All subjects must have an A455E mutation on at least 1 CFTR allele; no more than 10 subjects may have an F508del mutation on 1 CFTR allele.
  • (FEV1) ≥30% of predicted and ≤90% of predicted at the Screening Visit, based on the Global Lung Function Initiative (GLI)-2012 multi ethnic all-age reference equations.
  • Stable CF disease as judged by the investigator.
  • Willing to remain on a stable medication regimen for CF from 4 weeks before Day 1 through the Follow up Visit.

Exclusion criteria

Exclusion Criteria:

  • History of any comorbidity reviewed at the Screening Visit that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject.
  • A G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R, or R117H mutation on at least one CFTR allele.
  • Pregnant or breastfeeding.
  • Any abnormal laboratory values at the Screening Visit.
  • History of cataract/lens opacity, or evidence of cataract/lens opacity determined to be by the ophthalmologist or optometrist during the ophthalmologic examination at the Screening Visit.
  • Use of strong inhibitors or strong inducers of , including consumption of certain herbal medications and certain fruit and fruit juices, within 14 days before Day 1
  • Sexually active subjects of who are not willing to follow the requirements
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Treatment Sequence 1

    LUM/IVA in Treatment Period 1; washout; placebo in Treatment Period 2

    Drug: LUM/IVA · Drug: Placebo

  • Experimental
    Treatment Sequence 2

    Placebo in Treatment Period 1; washout; LUM/IVA in Treatment Period 2

    Drug: LUM/IVA · Drug: Placebo

Interventions

  • DrugLUM/IVA

    Drug pages: Lumacaftor · Ivacaftor

    LUM 400 mg/IVA 250 mg every 12 hours (q12h)

    Also known as: lumacaftor/ivacaftor

  • DrugPlacebo

    No Active Drug

06

What researchers measure

Primary outcomes

  1. Absolute Change From Study Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) Through Week 8

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

    Time frame: Study Baseline, Through Week 8

07

Results

Posted Oct 2, 2018

Participant flow

A total of 20 subjects were enrolled in this cross-over study.

Treatment Period 1 (8 Weeks)
Participant flow — Treatment Period 1 (8 Weeks)
MilestoneSequence 1: First LUM/IVA, Then PlaceboSequence 2: First Placebo, Then LUM/IVA
Started1010
Completed1010
Not completed00
Washout Period (8 Weeks)
Participant flow — Washout Period (8 Weeks)
MilestoneSequence 1: First LUM/IVA, Then PlaceboSequence 2: First Placebo, Then LUM/IVA
Started1010
Completed89
Not completed21
Withdrew: Adverse event21
Treatment Period 2 (8 Weeks)
Participant flow — Treatment Period 2 (8 Weeks)
MilestoneSequence 1: First LUM/IVA, Then PlaceboSequence 2: First Placebo, Then LUM/IVA
Started89
Completed89
Not completed00

Outcome measures

PrimaryAbsolute Change From Study Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) Through Week 8

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

Time frame:
Study Baseline, Through Week 8
Reported as:
Least squares mean · Percentage of predicted FEV1
Absolute Change From Study Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) Through Week 8
Percentage of predicted FEV1PlaceboLUM/IVA
Absolute Change From Study Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) Through Week 82.6 (0.2 to 4.9)2.7 (0.3 to 5.0)
Statistical analysis
  • Placebo vs LUM/IVA · Mixed Model Repeated Measure (MMRM) · p = 0.9277 · Least squares mean difference: 0.1 · 95% CI -2.5 to 2.7

Adverse events

Collected over Up to Week 28. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/18 (0%)0/18 (0%)13/18 (72.2%)
LUM/IVA0/19 (0%)0/19 (0%)15/19 (78.9%)
Most frequent other events
Showing 10 of 56
Most frequent other events
EventPlaceboLUM/IVA
DiarrhoeaGastrointestinal disorders0/188/19
HeadacheNervous system disorders0/184/19
FlatulenceGastrointestinal disorders0/184/19
NauseaGastrointestinal disorders0/184/19
Sputum increasedRespiratory, thoracic and mediastinal disorders3/183/19
CoughRespiratory, thoracic and mediastinal disorders3/182/19
DyspnoeaRespiratory, thoracic and mediastinal disorders3/182/19
Abdominal painGastrointestinal disorders3/182/19
FatigueGeneral disorders2/183/19
NasopharyngitisInfections and infestations2/183/19

Baseline characteristics

Age, Continuous
Age, Continuous(years)Sequence 1: First LUM/IVA, Then PlaceboSequence 2: First Placebo, Then LUM/IVATotal
Mean41.2 ± 15.134.7 ± 11.838.0 ± 13.6
Sex: Female, Male
Sex: Female, Male(Participants)Sequence 1: First LUM/IVA, Then PlaceboSequence 2: First Placebo, Then LUM/IVATotal
Female7512
Male358
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Sequence 1: First LUM/IVA, Then PlaceboSequence 2: First Placebo, Then LUM/IVATotal
Hispanic or Latino000
Not Hispanic or Latino101020
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Sequence 1: First LUM/IVA, Then PlaceboSequence 2: First Placebo, Then LUM/IVATotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White101020
More than one race000
Unknown or Not Reported000
08

Study locations

2 sites
  • HagaZiekenhuis
    Den Haag, Netherlands
  • University Medical Center, Utrecht, Department of Pulmonology and Tuberculosis
    Heidelberglaan, Netherlands
09

References and documents

Publications

  • Berkers G, van der Meer R, Heijerman H, Beekman JM, Boj SF, Vries RGJ, van Mourik P, Doyle JR, Audhya P, Yuan ZJ, Kinnman N, van der Ent CK. Lumacaftor/ivacaftor in people with cystic fibrosis with an A455E-CFTR mutation. J Cyst Fibros. 2021 Sep;20(5):761-767. doi: 10.1016/j.jcf.2020.11.007. Epub 2020 Nov 26. PubMed 33249003 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in Sep 2017, 7 months.

Results were first posted in Oct 2018, 1 year after primary completion.

Of 40 industry-sponsored phase 2 interventional studies under Cystic Fibrosis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 29. This study's 7 months is below that.

Counting every sponsor, half of 57 studies reached it within 21 months; a quarter within 9 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2017
First posted
Feb 23, 2017
StartActual
Jan 31, 2017
Primary completionActual
Sep 6, 2017
CompletionActual
Oct 4, 2017
Results first posted
Oct 2, 2018
Last update
Oct 2, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 2, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03061331
Responsible party
Sponsor
First posted
Feb 23, 2017
Start date
Jan 31, 2017
Primary completion
Sep 6, 2017
Completion
Oct 4, 2017
Results posted
Oct 2, 2018
Last update
Oct 2, 2018

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lumacaftor · Ivacaftor

Start the discussion